Results 71 to 80 of about 114,702 (262)

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors

Oncology, 2019
Background: Ibrutinib, a first-in-class, once-daily inhibitor of Bruton’s tyrosine kinase, is approved in the United States for the treatment of various B-cell malignancies.
D. Hong, D. Rasco, M. Veeder, J. Luke, J. Chandler, A. Balmanoukian, T. George, P. Munster, J. Berlin, M. Gutierrez, A. Mita, H. Wakelee, S. Samakoglu, S. Guan, I. Dimery, T. Graef, E. Borazanci   +16 more
semanticscholar   +1 more source

Bruton’s Tyrosine Kinase Inhibitors: Recent Updates

International Journal of Molecular Sciences
Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the landscape for the treatment of hematological malignancies, solid tumors, and, recently, autoimmune disorders. The BTK receptor is expressed in several hematopoietic cells such as macrophages, neutrophils, mast cells, and osteoclasts.
Amneh Fares, Carlos Carracedo Uribe, Diana Martinez, Tauseef Rehman, Carlos Silva Rondon, Jose Sandoval-Sus   +5 more
openaire   +2 more sources

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis

Postępy Psychiatrii i Neurologii, 2023
In this review, we have highlighted a new class of drugs, Bruton's tyrosine kinase (BTK) inhibitors, and summarized the results of recent clinical trials in the treatment of multiple sclerosis.Multiple sclerosis (MS) is considered an autoimmune disease of the central nervous system, in which B-lymphocytes and myeloid cells, such as macrophages and ...
Shulga, Olga, Chabanova, Anna, Kotsiuba, Oleksandra   +2 more
openaire   +2 more sources

The specificities of small molecule inhibitors of the TGF beta and BMP pathways [PDF]

, 2011
Small molecule inhibitors of type 1 receptor serine threonine kinases (ALKs1-7), the mediators of TGF beta and BMP signals, have been employed extensively to assess their physiological roles in cells and organisms. While all of these inhibitors have been
Sapkota, Gopal P., Traynor, Ryan, Vogt, Janis   +2 more
core   +3 more sources

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?

Cell Transplantation, 2020
Chronic lymphocytic leukemia (CLL), with an incidence rate between 4 and 6 cases per 100,000 persons per year, is considered the most prevalent leukemia in the western world.
Sara Bravaccini, Giovanni Martinelli, Claudio Cerchione   +2 more
doaj   +1 more source

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformation

Cancer, 2018
In a proportion of patients with chronic lymphocytic leukemia (CLL), resistance to Bruton tyrosine kinase (BTK) inhibitors (BTKi) is attributed to acquired BTK/phospholipase C gamma 2 (PLCG2) mutations.
R. Kanagal-Shamanna, P. Jain, Keyur Patel, M. Routbort, C. Bueso-Ramos, Tahani Alhalouli, Joseph D. Khoury, R. Luthra, A. Ferrajoli, M. Keating, N. Jain, J. Burger, Z. Estrov, W. Wierda, H. Kantarjian, L. J. Medeiros   +15 more
semanticscholar   +1 more source

Platelet Rubicon Bidirectional Regulation of GPVI and Integrin αIIbβ3 Signaling Mitigates Stroke Infarction Without Compromising Hemostasis

Advanced Science, EarlyView.
This study identifies Rubicon as a key platelet protein that bidirectionally regulates GPVI and integrin αIIbβ3 signaling. Platelet Rubicon protects against cerebral ischemia‐reperfusion injury by limiting infarction without increasing hemorrhage.
Xiaoyan Chen, Jingke Li, Yangyang Liu, Li Li, Xin Deng, Yilin Sheng, Xianyu Zhu, Xiao Jiang, Wei Li, Xueli Cai, Qiming Sun, Hu Hu   +11 more
wiley   +1 more source

Novel Bruton's tyrosine kinase inhibitors currently in development.

OncoTargets and therapy, 2013
Bruton's tyrosine kinase (Btk) is intimately involved in multiple signal-transduction pathways regulating survival, activation, proliferation, and differentiation of B-lineage lymphoid cells. Btk is overexpressed and constitutively active in several B-lineage lymphoid malignancies.
D’Cruz, Osmond J, Uckun, Fatih M
openaire   +2 more sources

Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans

Drug Metabolism And Disposition, 2018
Acalabrutinib is a targeted, covalent inhibitor of Bruton tyrosine kinase (BTK) with a unique 2-butynamide warhead that has relatively lower reactivity than other marketed acrylamide covalent inhibitors. A human [14C] microtracer bioavailability study in
T. Podoll, P. Pearson, Jerry B. Evarts, Timothy G Ingallinera, E. Bibikova, Hao Sun, Mark A. Gohdes, Kristen A. Cardinal, M. Sanghvi, Greg Slatter   +9 more
semanticscholar   +1 more source

Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells

Clinical & Translational Immunology, 2021
Bruton's tyrosine kinase (BTK) plays a non‐redundant signaling role downstream of the B‐cell receptor (BCR) in B cells and the receptors for the Fc region of immunoglobulins (FcR) in myeloid cells.
E. Bame, Hao Tang, J. Burns, M. Arefayene, Klaus Michelsen, Bin Ma, Isaac E Marx, R. Prince, A. Roach, Urjana Poreci, Douglas Donaldson, P. Cullen, Fergal Casey, Jing Zhu, Thomas M. Carlile, D. Sangurdekar, Baohong Zhang, Patrick E. Trapa, Joseph C Santoro, Param Muragan, A. Pellerin, S. Rubino, D. Gianni, Bekim Bajrami, Xiaomei Peng, A. Coppell, K. Riester, S. Belachew, D. Mehta, Mike Palte, B. Hopkins, Matthew Scaramozza, N. Franchimont, M. Mingueneau   +33 more
semanticscholar   +1 more source